DelveInsight’s “Septic Shock Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Septic Shock market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Septic Shock drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Septic Shock treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Septic Shock: An Overview
Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection. Sepsis can be the clinical manifestation of infections acquired both in the community setting and in health care facilities. Anyone affected by an infection, severe injury, or serious non-communicable disease can progress to sepsis, but vulnerable populations are at higher risk, including older persons, pregnant or recently pregnant women, neonates, hospitalized patients, patients in intensive care units, etc.
The symptoms of sepsis include fever or low temperature and shivering, altered mental status, difficulty breathing/rapid breathing, increased heart rate, weak pulse/low blood pressure, low urine output, cyanotic or mottled skin, cold extremities, and extreme body pain or discomfort.
The risk of septic shock is higher in newborns and infants, elderly people, pregnant women, and individuals with chronic diseases. The chronic diseases that increase the risk of septic shock include diabetes, cirrhosis, cancer, AIDS/HIV, and kidney and heart disease.
The pathogenesis involves a complex response of cellular activation that triggers the release of a multitude of proinflammatory mediators. This inflammatory response causes activation of leukocytes and endothelial cells, as well as activation of the coagulation system. Cytokines tumor necrosis factor-alpha (TNF-α) and interleukin-1 (IL-1) are central to the pathophysiology of septic shock and act synergistically to induce hypotension in experimental models, a number of other vital mediators are also known to play a major role including high-mobility group box 1 (HMGB1) protein.
Septic Shock Market Key Facts
-
As per the study conducted by Hari et al. (2017), titled “Epidemiology of sepsis and septic shock in critical care units: comparison between sepsis-2 and sepsis-3 populations using a national critical care database” shows that the sepsis-2 septic shock and sepsis-3 septic shock accounted for 23.4%, and 6.0%, respectively, of admissions to adult general ICUs in England over the five year period.
-
Sepsis-2 septic shock accounted for three-quarters of the severe sepsis population, and the extrapolated population incidence increased from 69 to 79 per 100,000 person-years. In contrast, sepsis-3 septic shock was only one-fifth of the sepsis population and with minimal change in the extrapolated population incidence over the 5-year period (approximately 19 per 100,000 person-years).
-
The study conducted by Quenot et al. (2013), titled “The epidemiology of septic shock in French intensive care units: the prospective multicenter cohort EPISS study,” among patients admitted to participating ICUs between October 2009 and September 2011, 13.7% of patients had septic shock.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Septic Shock pipeline therapies. It also thoroughly assesses the Septic Shock market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Septic Shock drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Septic Shock Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Septic Shock epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Septic Shock epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Septic Shock Epidemiology, Segmented as –
-
Total Incident Cases of Septic Shock in the 7MM [2019–2032]
-
Gender-specific Incident Cases of Septic Shock in the 7MM [2019–2032]
-
Treatable Cases of Septic Shock in the 7MM [2019–2032]
Septic Shock Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Septic Shock market or expected to be launched during the study period. The analysis covers the Septic Shock market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Septic Shock drugs based on their sale and market share.
The report also covers the Septic Shock pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Septic Shock companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Septic Shock Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/septic-shock-market
Septic Shock Therapeutics Analysis
The medications used in septic shock include intravenous antibiotics, vasopressors, inotropic drugs, insulin, and corticosteroids.
Broad-spectrum antibiotics are administered in patients experiencing septic shock (within 1 h of recognition of septic shock) and sepsis without septic shock. The choice of antibiotics depends on the patient’s immunity, the source of the infection, and the causative microorganism.
Typically, broad-spectrum gram-positive and gram-negative bacterial coverage is used initially; immunocompromised patients should also receive an empiric antifungal drug. Common antibiotics for empiric gram-positive coverage include vancomycin and linezolid. Empiric gram-negative antibiotics include broad-spectrum penicillins (piperacillin, tazobactam), 3rd- or 4th-generation cephalosporins, imipenems, and aminoglycosides.
To further improve the treatment scenario, several major pharma and biotech companies are developing therapies for Septic Shock. Currently, Adrenomed is leading the therapeutics with its Septic Shock drug candidates in the most advanced stage of clinical development.
Septic Shock Companies Actively Working in the Therapeutics Market Include
-
Adrenomed AG
-
AM-Pharma
-
Atox Bio
-
Inotrem
-
LaJolla Pharmaceutical Company
-
MYND LifeSciences
-
Northern Therapeutics
-
Pharmazz
-
Vivacelle Bio
And Many Others
Emerging and Marketed Septic Shock Therapies Covered in the Report Include:
-
Adrecizumab: Adrenomed
-
Nangibotide: Inotrem
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/septic-shock-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Septic Shock Competitive Intelligence Analysis
4. Septic Shock Market Overview at a Glance
5. Septic Shock Disease Background and Overview
6. Septic Shock Patient Journey
7. Septic Shock Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Septic Shock Treatment Algorithm, Current Treatment, and Medical Practices
9. Septic Shock Unmet Needs
10. Key Endpoints of Septic Shock Treatment
11. Septic Shock Marketed Therapies
12. Septic Shock Emerging Drugs and Latest Therapeutic Advances
13. Septic Shock Seven Major Market Analysis
14. Attribute Analysis
15. Septic Shock Market Outlook (In US, EU5, and Japan)
16. Septic Shock Companies Active in the Market
17. Septic Shock Access and Reimbursement Overview
18. KOL Views on the Septic Shock Market
19. Septic Shock Market Drivers
20. Septic Shock Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/septic-shock-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Congestive Heart Failure Market
“Congestive Heart Failure Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Congestive Heart Failure market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Congestive Heart Failure market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/medical-devices